Clinical Trial Detail

NCT ID NCT03199586
Title Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Novita Pharmaceuticals, Inc.
Indications

lymphoma

ovarian cancer

liver cancer

pancreatic cancer

esophageal cancer

lung cancer

breast cancer

colon cancer

prostate cancer

Therapies

NP-G2-044

Age Groups: adult senior

No variant requirements are available.